HRP20110007T1 - Smanjivanje potencijalnih jatrogenskih rizika povezanih s cjepivima protiv gripe - Google Patents
Smanjivanje potencijalnih jatrogenskih rizika povezanih s cjepivima protiv gripe Download PDFInfo
- Publication number
- HRP20110007T1 HRP20110007T1 HR20110007T HRP20110007T HRP20110007T1 HR P20110007 T1 HRP20110007 T1 HR P20110007T1 HR 20110007 T HR20110007 T HR 20110007T HR P20110007 T HRP20110007 T HR P20110007T HR P20110007 T1 HRP20110007 T1 HR P20110007T1
- Authority
- HR
- Croatia
- Prior art keywords
- vaccine
- virus
- degree
- influenza
- culture
- Prior art date
Links
- 229960003971 influenza vaccine Drugs 0.000 title claims 2
- 230000003247 decreasing effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 13
- 229960005486 vaccine Drugs 0.000 claims abstract 12
- 244000052769 pathogen Species 0.000 claims abstract 5
- 238000012360 testing method Methods 0.000 claims abstract 3
- 241000700605 Viruses Species 0.000 claims 4
- 238000001514 detection method Methods 0.000 claims 3
- 239000012678 infectious agent Substances 0.000 claims 3
- 241000711904 Pneumoviridae Species 0.000 claims 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 241000712461 unidentified influenza virus Species 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 1
- 241001466953 Echovirus Species 0.000 claims 1
- 241000709661 Enterovirus Species 0.000 claims 1
- 241000287828 Gallus gallus Species 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 241000712045 Morbillivirus Species 0.000 claims 1
- 241000711504 Paramyxoviridae Species 0.000 claims 1
- 241000709664 Picornaviridae Species 0.000 claims 1
- 241000711902 Pneumovirus Species 0.000 claims 1
- 241000702247 Reoviridae Species 0.000 claims 1
- 241000702670 Rotavirus Species 0.000 claims 1
- 241000710799 Rubella virus Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 235000013601 eggs Nutrition 0.000 claims 1
- 230000000984 immunochemical effect Effects 0.000 claims 1
- 229940031551 inactivated vaccine Drugs 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 238000011081 inoculation Methods 0.000 claims 1
- 229940124590 live attenuated vaccine Drugs 0.000 claims 1
- 229940023012 live-attenuated vaccine Drugs 0.000 claims 1
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 229940031346 monovalent vaccine Drugs 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 238000000751 protein extraction Methods 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 229940031626 subunit vaccine Drugs 0.000 claims 1
- 229960000172 trivalent influenza vaccine Drugs 0.000 claims 1
- 229940031418 trivalent vaccine Drugs 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000011109 contamination Methods 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 210000003501 vero cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
Abstract
Postupak za pripremanje cjepiva protiv gripe iz virusa gripe izraslog u kulturi MDCK stanične linije, koji sadrži stupanj u kojem se uzgojeni virus i/ili cjepivo i/ili kultura testira na prisutnost infekcijskog agensa koji može rasti u navedenoj staničnoj liniji, ali koji ne raste u embriju kokošjih jaja, naznačen time, da je navedeni infekcijski agens jedan ili više od sljedećih patogena: Reoviridae kod sisavaca; Pneumoviridae; Pneumovirusi od Pneumoviridae; Morbillivirusi iz familije Paramyxoviridae; Echovirusi od Enterovirusa iz familije Picornaviridae ; ili Rotavirus. Patent sadrži još 11 patentnih zahtjeva.
Claims (12)
1. Postupak za pripremanje cjepiva protiv gripe iz virusa gripe izraslog u kulturi MDCK stanične linije, koji sadrži stupanj u kojem se uzgojeni virus i/ili cjepivo i/ili kultura testira na prisutnost infekcijskog agensa koji može rasti u navedenoj staničnoj liniji, ali koji ne raste u embriju kokošjih jaja, naznačen time, da je navedeni infekcijski agens jedan ili više od sljedećih patogena: Reoviridae kod sisavaca; Pneumoviridae; Pneumovirusi od Pneumoviridae; Morbillivirusi iz familije Paramyxoviridae; Echovirusi od Enterovirusa iz familije Picornaviridae ; ili Rotavirus.
2. Postupak prema patentnom zahtjevu 1, naznačen time, da infekcijski agens jest jedan ili više od sljedećih patogena: respiratorni sincicijski virus (RSV); virus rubeole.
3. Postupak prema patentnom zahtjevu 1, naznačen time, da nadalje sadrži jedan ili više od sljedećih stupnjeva: stupanj inaktivacije; stupanj miješanja tri virusna soja da se napravi trovalentno cjepivo; stupanj formuliranja cjepiva za injektiranje; stupanj združivanja cjepiva s adjuvansom; stupanj mjerenja sadržaja HA; stupanj podešavanja sadržaja HA, na pr. razrjeđivanjem; stupanj dodavanja konzervansa; stupanj odstranjivanja rezidualnih nukleinskih kiselina koje pripadaju stanici domaćina.
4. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se kultura testira imunokemijskom detekcijom; testovima inokulacije stanične kulture i/ili detekcijom nukleinske kiseline.
5. Postupak prema patentnom zahtjevu 4, naznačen time, da se detekcija provodi metodom ELISA i/ili PCR.
6. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se testiranje provodi kod jednog od sljedećih stupnjeva: virusna infekcija, stadiji rasta, prikupljanje virusa, procesuiranje virusa, razdvajanje, ekstrakcija membranskih proteina, formuliranje cjepiva, pakiranje cjepiva.
7. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da cjepivo jest živo atenuirano cjepivo.
8. Postupak prema bilo kojem od patentnih zahtjeva 1-6, naznačen time, da cjepivo jest inaktivirano cjepivo.
9. Postupak prema patentnom zahtjevu 8, naznačen time, da cjepivo jest cjelostanično, fragmentirano ili subjunitno cjepivo.
10. Postupak prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time, da cjepivo jest trovalentno cjepivo protiv gripe.
11. Postupak prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time, da cjepivo jest monovalentno cjepivo protiv pandemijske gripe.
12. Postupak prema patentnom zahtjevu 11, naznačen time, da cjepivo uključuje soj H5 ili H7 virusa gripe.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04255471 | 2004-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110007T1 true HRP20110007T1 (hr) | 2011-04-30 |
Family
ID=35520177
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100673T HRP20100673T1 (hr) | 2004-09-09 | 2005-09-09 | Smanjivanje potencijalnih jatrogenskih rizika povezanih s cjepivima protiv gripe |
| HR20110007T HRP20110007T1 (hr) | 2004-09-09 | 2011-01-05 | Smanjivanje potencijalnih jatrogenskih rizika povezanih s cjepivima protiv gripe |
| HRP20120640TT HRP20120640T1 (hr) | 2004-09-09 | 2012-08-07 | Smanjenje potencijalnih jatrogenih rizika vezanih uz cjepiva protiv gripe |
| HRP20130962TT HRP20130962T1 (hr) | 2004-09-09 | 2013-10-10 | Smanjenje potencijalnih iatrogenih rizika povezanih sa antigenima cjepiva |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100673T HRP20100673T1 (hr) | 2004-09-09 | 2005-09-09 | Smanjivanje potencijalnih jatrogenskih rizika povezanih s cjepivima protiv gripe |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120640TT HRP20120640T1 (hr) | 2004-09-09 | 2012-08-07 | Smanjenje potencijalnih jatrogenih rizika vezanih uz cjepiva protiv gripe |
| HRP20130962TT HRP20130962T1 (hr) | 2004-09-09 | 2013-10-10 | Smanjenje potencijalnih iatrogenih rizika povezanih sa antigenima cjepiva |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US8119337B2 (hr) |
| EP (5) | EP1789084B1 (hr) |
| JP (7) | JP2008512443A (hr) |
| AT (2) | ATE489965T1 (hr) |
| CA (2) | CA2890962A1 (hr) |
| CY (3) | CY1111180T1 (hr) |
| DE (3) | DE12193096T1 (hr) |
| DK (4) | DK2236155T3 (hr) |
| ES (4) | ES2432655T3 (hr) |
| HR (4) | HRP20100673T1 (hr) |
| PL (4) | PL2236155T3 (hr) |
| PT (4) | PT2179744E (hr) |
| RS (3) | RS51665B (hr) |
| SI (4) | SI1789084T1 (hr) |
| WO (1) | WO2006027698A1 (hr) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008512443A (ja) | 2004-09-09 | 2008-04-24 | カイロン ベーリング ゲーエムベーハー アンド カンパニー | インフルエンザワクチンに関連する潜在的医原性リスクの減少 |
| ES2310062B1 (es) | 2005-07-15 | 2009-11-13 | Bionostra, S.L. | Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones. |
| EP1951296B2 (en) * | 2005-11-01 | 2014-07-23 | Novartis Vaccines and Diagnostics GmbH | Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment |
| AU2006310339B2 (en) | 2005-11-04 | 2013-01-10 | Novartis Ag | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| EA014028B1 (ru) | 2005-11-04 | 2010-08-30 | Новартис Вэксинс Энд Диагностикс Срл | Эмульсии, содержащие свободное поверхностно-активное вещество в водной фазе в качестве адъюванта сплит вакцин против гриппа |
| NZ594482A (en) | 2005-11-04 | 2012-11-30 | Novartis Vaccines & Diagnostic | Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant |
| AU2006310337B9 (en) | 2005-11-04 | 2013-11-28 | Novartis Ag | Adjuvanted influenza vaccines including cytokine-inducing agents |
| PL2368572T3 (pl) | 2005-11-04 | 2020-11-16 | Seqirus UK Limited | Szczepionki z adjuwantem z niewirionowymi antygenami otrzymane z wirusów grypy hodowanych w hodowli komórkowej |
| EP2478916B1 (en) | 2006-01-27 | 2020-04-01 | Seqirus UK Limited | Influenza vaccines containing hemagglutinin and matrix proteins |
| JP2009534303A (ja) | 2006-03-24 | 2009-09-24 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー | 冷蔵しないインフルエンザワクチンの保存 |
| JP2009532352A (ja) | 2006-03-31 | 2009-09-10 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | ワクチンのための高力価組み換えインフルエンザ・ウィルス |
| GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| BRPI0716536A2 (pt) | 2006-09-11 | 2013-09-24 | Novartis Ag | produÇço de vacinas de vÍrus influenza, sem a utilizaÇço de ovos |
| WO2008059018A2 (en) * | 2006-11-15 | 2008-05-22 | Intervet International B.V. | Vaccine for vaccinating felines and canines against influenza virus |
| EP2121011B1 (en) | 2006-12-06 | 2014-05-21 | Novartis AG | Vaccines including antigen from four strains of influenza virus |
| US9474798B2 (en) | 2007-06-18 | 2016-10-25 | Wisconsin Alumni Research Foundation | Influenza M2 protein mutant viruses as live influenza attenuated vaccines |
| CN101784283A (zh) | 2007-06-27 | 2010-07-21 | 诺华有限公司 | 低添加流感疫苗 |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| JP5518041B2 (ja) | 2008-03-18 | 2014-06-11 | ノバルティス アーゲー | インフルエンザウイルスワクチン抗原の調製における改良 |
| JP2012507272A (ja) | 2008-11-05 | 2012-03-29 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 新規な方法 |
| KR20110132373A (ko) | 2009-02-10 | 2011-12-07 | 노파르티스 아게 | 유행병-연관 주에 대한 인플루엔자 백신 요법 |
| EA023662B1 (ru) | 2009-02-10 | 2016-06-30 | Новартис Аг | Вакцины против гриппа со сниженным количеством сквалена |
| CA2752041A1 (en) | 2009-02-10 | 2010-08-19 | Novartis Ag | Influenza vaccines with increased amounts of h3 antigen |
| USH2283H1 (en) | 2009-04-27 | 2013-09-03 | Novartis Ag | Vaccines for protecting against influenza |
| AU2010293902A1 (en) | 2009-09-10 | 2012-03-22 | Novartis Ag | Combination vaccines against respiratory tract diseases |
| JP2013507990A (ja) | 2009-10-26 | 2013-03-07 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス |
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| CN102858961A (zh) * | 2010-05-03 | 2013-01-02 | 葛兰素史密丝克莱恩生物有限公司 | 新方法 |
| EP2571520B1 (en) | 2010-05-21 | 2018-04-04 | Seqirus UK Limited | Influenza virus reassortment method |
| AU2011262309B2 (en) | 2010-06-01 | 2015-08-13 | Seqirus UK Limited | Concentration of influenza vaccine antigens without lyophilization |
| CA2801151A1 (en) | 2010-06-01 | 2011-12-08 | Novartis Ag | Concentration of vaccine antigens with lyophilization |
| GB201011502D0 (en) | 2010-07-08 | 2010-08-25 | Glaxosmithkline Biolog Sa | Novel process |
| EP2605792B1 (en) | 2010-08-20 | 2014-12-10 | Novartis AG | Soluble needle arrays for delivery of influenza vaccines |
| WO2012032482A1 (en) | 2010-09-07 | 2012-03-15 | Novartis Ag | Generic assays for detection of mammalian reovirus |
| WO2012114312A2 (en) | 2011-02-25 | 2012-08-30 | Novartis Ag | Exogenous internal positive control |
| AU2012324398A1 (en) | 2011-10-20 | 2014-05-01 | Seqirus UK Limited | Adjuvanted influenza B virus vaccines for pediatric priming |
| ES2564138T3 (es) * | 2011-12-12 | 2016-03-18 | Novartis Ag | Ensayo para Hemaglutinina del virus de la influenza |
| GB201218195D0 (en) | 2012-10-10 | 2012-11-21 | Istituto Zooprofilattico Sperimentale Delle Venezie | Composition |
| EP3022296B1 (en) | 2013-07-15 | 2022-12-28 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs |
| BE1023557B1 (fr) | 2014-02-10 | 2017-05-03 | Univercells Sa | Systeme, appareil et procede pour la production de biomolecules |
| RU2628800C2 (ru) * | 2014-03-12 | 2017-08-22 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами |
| US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| AU2015252119A1 (en) | 2014-11-07 | 2016-05-26 | Takeda Vaccines, Inc. | Hand, foot, and mouth vaccines and methods of manufacture and use thereof |
| AR102547A1 (es) | 2014-11-07 | 2017-03-08 | Takeda Vaccines Inc | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso |
| US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
| EP3313439A2 (en) | 2015-06-26 | 2018-05-02 | Seqirus UK Limited | Antigenically matched influenza vaccines |
| WO2017007839A1 (en) | 2015-07-06 | 2017-01-12 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza virus replication for vaccine development |
| US10416171B2 (en) | 2015-07-07 | 2019-09-17 | Seqirus UK Limited | Influenza potency assays |
| US11197925B2 (en) | 2016-02-19 | 2021-12-14 | Wisconsin Alumni Research Foundation (Warf) | Influenza B virus replication for vaccine development |
| WO2019084310A1 (en) | 2017-10-25 | 2019-05-02 | Yoshihiro Kawaoka | HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION |
| MX2020004151A (es) | 2017-10-30 | 2020-08-13 | Takeda Pharmaceuticals Co | Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos. |
| CA3081586A1 (en) | 2017-11-03 | 2019-05-09 | Takeda Vaccines, Inc. | Zika vaccines and immunogenic compositions, and methods of using the same |
| WO2020033527A2 (en) | 2018-08-07 | 2020-02-13 | Wisconsin Alumni Research Foundation (Warf) | Recombinant biologically contained filovirus vaccine |
| EP3840780A1 (en) | 2018-08-20 | 2021-06-30 | Wisconsin Alumni Research Foundation | Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (ha) protein |
| US20210324483A1 (en) * | 2018-10-15 | 2021-10-21 | Regenxbio Inc. | Method for measuring the infectivity of replication defective viral vectors and viruses |
| WO2020167432A2 (en) | 2019-01-23 | 2020-08-20 | Yoshihiro Kawaoka | Mutations that confer genetic stability to additional genes in influenza viruses |
| EP3921413A1 (en) | 2019-02-08 | 2021-12-15 | Wisconsin Alumni Research Foundation (WARF) | Humanized cell line |
| WO2020223699A1 (en) | 2019-05-01 | 2020-11-05 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza virus replication for vaccine development |
| AU2020269164B2 (en) | 2019-05-08 | 2024-04-04 | Takeda Vaccines, Inc. | Inactivated virus compositions and Zika vaccine formulations |
| WO2021041624A2 (en) | 2019-08-27 | 2021-03-04 | Yoshihiro Kawaoka | Recombinant influenza viruses with stabilized ha for replication in eggs |
| BR112022009545A2 (pt) | 2019-11-18 | 2022-10-11 | Seqirus Pty Ltd | Método para produzir vírus influenza recombinantes |
| US11739303B2 (en) * | 2020-01-24 | 2023-08-29 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized NA |
| WO2021195410A1 (en) | 2020-03-25 | 2021-09-30 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| US20240139306A1 (en) * | 2021-03-01 | 2024-05-02 | Iowa State University Research Foundation, Inc. | Methods and compositions for detecting and producing porcine morbillivirus and vaccines thereof |
| CN114107392A (zh) * | 2021-11-22 | 2022-03-01 | 昆明理工大学 | 一种cvb5病毒类病毒样颗粒的制备方法 |
| WO2023154043A1 (en) | 2022-02-09 | 2023-08-17 | Takeda Vaccines, Inc. | Zika vaccines and immunogenic compositions, and methods of using the same |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4193991A (en) | 1978-12-20 | 1980-03-18 | Cornell Research Foundation, Inc. | Canine parvovirus vaccine |
| EP0261955A3 (en) * | 1986-09-26 | 1989-06-07 | E.I. Du Pont De Nemours And Company | Process for immobilization of dna |
| US6284492B1 (en) * | 1988-02-26 | 2001-09-04 | Large Scale Biology Corporation | Recombinant animal viral nucleic acids |
| CA2054228A1 (en) | 1990-10-30 | 1992-05-01 | Masaharu Oki | Muramyldipeptide derivatives and influenza vaccine comprising the derivatives |
| JPH0813753B2 (ja) * | 1992-05-22 | 1996-02-14 | 株式会社微生物化学研究所 | 牛伝染性鼻気管炎ウイルス感染症、牛ウイルス性下痢−粘膜病ウイルス感染症、パラインフルエンザ３型ウイルス感染症、牛ｒｓウイルス感染症および牛アデノ７型ウイルス感染症５種混合生ワクチン |
| IL103939A (en) * | 1992-12-01 | 1996-09-12 | Abic Ltd | An anti-DBI vaccine in birds containing attenuated live DBI virus |
| CA2156525A1 (en) | 1993-02-19 | 1994-09-01 | Susan Dillon | Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a |
| DE4311580C1 (de) * | 1993-04-12 | 1994-08-18 | Werner Prof Dr Med Reutter | Glycoproteine, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Mittel |
| US5824536A (en) * | 1994-08-23 | 1998-10-20 | St. Jude Children's Research Hospital | Influenza virus replicated in mammalian cell culture and vaccine production |
| EP0791055B1 (en) | 1994-11-10 | 2012-01-25 | Baxter Healthcare S.A. | Method for producing biologicals in protein-free culture |
| US6146873A (en) * | 1994-11-10 | 2000-11-14 | Baxter Aktiengesellschaft | Production of orthomyxoviruses in monkey kidney cells using protein-free media |
| GB9500788D0 (en) | 1995-01-16 | 1995-03-08 | Medeva Holdings Bv | Vaccine compositions |
| DE19612967A1 (de) * | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
| DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
| JPH1175833A (ja) * | 1997-06-23 | 1999-03-23 | Chemo Sero Therapeut Res Inst | トリレオウイルスの調製法 |
| GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
| CN1309708A (zh) | 1997-12-11 | 2001-08-22 | 萨斯喀彻温大学 | 来源于猪的断奶后多系统消耗综合症病毒 |
| GB9804632D0 (en) * | 1998-03-05 | 1998-04-29 | Cantab Pharma Res | Virus preparations and methods |
| AT408615B (de) | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
| US6855544B1 (en) * | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
| GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
| EP1103610A1 (en) * | 1999-11-26 | 2001-05-30 | Introgene B.V. | Production of vaccines from immortalised mammalian cell lines |
| US7192759B1 (en) * | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
| DOP2000000109A (es) * | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
| TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
| DE10144906B4 (de) | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
| DE10144903A1 (de) * | 2001-09-12 | 2003-03-27 | Chiron Behring Gmbh & Co | Vermehrung von Viren in Zellkultur |
| FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
| KR101229202B1 (ko) * | 2002-04-26 | 2013-02-01 | 메디뮨 엘엘씨 | 인플루엔자 바이러스의 생산을 위한 다중 플라스미드 시스템 |
| DE10221836A1 (de) * | 2002-05-16 | 2003-12-04 | Lohmann Animal Health Gmbh | Attenuierung von Metapneumovirus |
| EP2287288B1 (en) * | 2002-07-09 | 2012-11-07 | Baxter International Inc. | Animal protein free media for cultivation of cells |
| JP3957188B2 (ja) * | 2002-10-25 | 2007-08-15 | ▲あき▼夫 友田 | 抗ウィルス剤 |
| CA2514653A1 (en) | 2003-01-30 | 2004-08-12 | Medimmune, Inc. | Uses of integrin alphavbeta3 antagonists |
| CA2523319A1 (en) * | 2003-04-25 | 2004-11-11 | Medimmune Vaccines, Inc. | Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| JP2008512443A (ja) * | 2004-09-09 | 2008-04-24 | カイロン ベーリング ゲーエムベーハー アンド カンパニー | インフルエンザワクチンに関連する潜在的医原性リスクの減少 |
| CA2690668C (en) | 2007-06-14 | 2014-08-19 | The Board Of Regents For Oklahoma State University | Vaccines containing canine parvovirus genetic variants |
-
2005
- 2005-09-09 JP JP2007530801A patent/JP2008512443A/ja not_active Withdrawn
- 2005-09-09 DK DK10075310T patent/DK2236155T3/da active
- 2005-09-09 ES ES12193096T patent/ES2432655T3/es active Active
- 2005-09-09 ES ES10075310T patent/ES2386272T3/es active Active
- 2005-09-09 US US11/662,481 patent/US8119337B2/en not_active Expired - Fee Related
- 2005-09-09 PT PT09075377T patent/PT2179744E/pt unknown
- 2005-09-09 DK DK09075377T patent/DK2179744T3/da active
- 2005-09-09 EP EP05795012A patent/EP1789084B1/en active Active
- 2005-09-09 CA CA2890962A patent/CA2890962A1/en not_active Abandoned
- 2005-09-09 EP EP20100075310 patent/EP2236155B1/en not_active Revoked
- 2005-09-09 EP EP20120193096 patent/EP2578229B1/en not_active Revoked
- 2005-09-09 PT PT10075310T patent/PT2236155E/pt unknown
- 2005-09-09 DE DE2021193096 patent/DE12193096T1/de active Pending
- 2005-09-09 ES ES05795012T patent/ES2357747T3/es active Active
- 2005-09-09 SI SI200531223T patent/SI1789084T1/sl unknown
- 2005-09-09 CA CA2579859A patent/CA2579859C/en not_active Expired - Fee Related
- 2005-09-09 AT AT09075377T patent/ATE489965T1/de active
- 2005-09-09 PT PT121930960T patent/PT2578229E/pt unknown
- 2005-09-09 AT AT05795012T patent/ATE488248T1/de active
- 2005-09-09 EP EP12157945.2A patent/EP2471551B1/en active Active
- 2005-09-09 PL PL10075310T patent/PL2236155T3/pl unknown
- 2005-09-09 RS RSP20110084 patent/RS51665B/en unknown
- 2005-09-09 PT PT05795012T patent/PT1789084E/pt unknown
- 2005-09-09 SI SI200531234T patent/SI2179744T1/sl unknown
- 2005-09-09 PL PL09075377T patent/PL2179744T3/pl unknown
- 2005-09-09 PL PL05795012T patent/PL1789084T3/pl unknown
- 2005-09-09 PL PL12193096T patent/PL2578229T3/pl unknown
- 2005-09-09 DK DK05795012.3T patent/DK1789084T3/da active
- 2005-09-09 HR HR20100673T patent/HRP20100673T1/hr unknown
- 2005-09-09 SI SI200531776T patent/SI2578229T1/sl unknown
- 2005-09-09 DK DK12193096T patent/DK2578229T3/da active
- 2005-09-09 SI SI200531559T patent/SI2236155T1/sl unknown
- 2005-09-09 RS RSP20110075 patent/RS51721B/en unknown
- 2005-09-09 EP EP20090075377 patent/EP2179744B1/en active Active
- 2005-09-09 DE DE602005024827T patent/DE602005024827D1/de active Active
- 2005-09-09 WO PCT/IB2005/003266 patent/WO2006027698A1/en active Application Filing
- 2005-09-09 RS RS20120317A patent/RS52400B/en unknown
- 2005-09-09 DE DE200560025170 patent/DE602005025170D1/de active Active
- 2005-09-09 ES ES09075377T patent/ES2357752T3/es active Active
-
2011
- 2011-01-05 HR HR20110007T patent/HRP20110007T1/hr unknown
- 2011-02-09 CY CY20111100152T patent/CY1111180T1/el unknown
- 2011-02-16 CY CY20111100197T patent/CY1111208T1/el unknown
- 2011-07-19 JP JP2011158471A patent/JP2011207911A/ja not_active Withdrawn
- 2011-10-14 US US13/274,285 patent/US9220768B2/en not_active Expired - Fee Related
- 2011-11-08 JP JP2011244904A patent/JP2012025784A/ja not_active Withdrawn
-
2012
- 2012-08-07 CY CY20121100706T patent/CY1113225T1/el unknown
- 2012-08-07 HR HRP20120640TT patent/HRP20120640T1/hr unknown
-
2013
- 2013-01-10 US US13/738,929 patent/US8460914B2/en active Active
- 2013-01-11 US US13/740,100 patent/US9358280B2/en not_active Expired - Fee Related
- 2013-02-20 JP JP2013030624A patent/JP2013100358A/ja not_active Withdrawn
- 2013-10-10 HR HRP20130962TT patent/HRP20130962T1/hr unknown
-
2015
- 2015-08-06 JP JP2015155818A patent/JP2015205929A/ja active Pending
-
2016
- 2016-05-09 US US15/150,214 patent/US10155932B2/en active Active
- 2016-11-29 JP JP2016230896A patent/JP2017057209A/ja not_active Withdrawn
-
2018
- 2018-11-08 US US16/184,482 patent/US10954493B2/en active Active
-
2019
- 2019-08-08 JP JP2019146040A patent/JP2019210292A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110007T1 (hr) | Smanjivanje potencijalnih jatrogenskih rizika povezanih s cjepivima protiv gripe | |
| CA2250078C (en) | Processes for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process | |
| CN102482647B (zh) | 以高效价制备用于疫苗制备的脊髓灰质炎病毒 | |
| JP2012025784A5 (hr) | ||
| JP2008512443A5 (hr) | ||
| US20080193478A1 (en) | Inactivated Poliomyelitis Vaccine Derived From Sabin Strain Of Polio Virus | |
| CN107460156B (zh) | 无血清全悬浮mdck细胞株及其在生产流感病毒中的应用 | |
| AR126891A2 (es) | Vacunas de subunidades de rotavirus, métodos de preparación y uso de las mismas | |
| US10463741B2 (en) | Non-gelatin vaccine protectant composition and live attenuated influenza vaccine | |
| Bonfante et al. | Susceptibility and intra-species transmission of the H9N2 G1 prototype lineage virus in Japanese quail and turkeys | |
| Abolnik et al. | Experimental infection of racing pigeons (Columba livia domestica) with highly pathogenic Clade 2.3. 4.4 sub-group B H5N8 avian influenza virus | |
| Shcherbik et al. | Evaluation of A (H1N1) pdm09 LAIV vaccine candidates stability and replication efficiency in primary human nasal epithelial cells | |
| Shichinohe et al. | Potency of an inactivated influenza vaccine prepared from a non-pathogenic H5N1 virus against a challenge with antigenically drifted highly pathogenic avian influenza viruses in chickens | |
| Zhang et al. | Isolation of swine influenza A virus in cell cultures and embryonated chicken eggs | |
| Stavaru et al. | Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania: Preclinical evaluation of split virion inactivated H5N1 vaccine with adjuvant | |
| CN103923885B (zh) | 鸡传染性法氏囊病毒Vero细胞适应株及其应用 | |
| BRPI0914805B1 (pt) | método para replicar vírus em uma cultura de células scldk, processo para adaptar células cldk dependentes do substrato para desenvolvimento em suspensão, método para propagar continuamente células scldk em suspensão, e, composição | |
| Cliquet et al. | The fluorescent antibody virus neutralization test | |
| CN107557346B (zh) | 一株h9亚型低致病性禽流感病毒及其应用 | |
| Wang et al. | Pathogenicity, immunogenicity, and protective ability of an attenuated SARS-CoV-2 variant with a deletion at the S1/S2 junction of the spike protein | |
| Faizuloev et al. | Biological characterization of cold-adapted SARS-CoV-2 variants | |
| CN102234637B (zh) | 重组甲型h1n1流感病毒灭活疫苗株(sc/pr8)的制备及应用 | |
| RU2323740C1 (ru) | ШТАММ "НОВОСИБИРСКИЙ" ВИРУСА ГРИППА ПТИЦ Influenzae virus avicum ДЛЯ КОНТРОЛЯ ИММУНОГЕННОЙ И АНТИГЕННОЙ АКТИВНОСТИ ВАКЦИН И ИЗГОТОВЛЕНИЯ БИОПРЕПАРАТОВ ДЛЯ ДИАГНОСТИКИ И СПЕЦИФИЧЕСКОЙ ПРОФИЛАКТИКИ ГРИППА ПТИЦ | |
| Nechaeva et al. | Study of immunogenicity and protective efficacy of live MDCK-derived pandemic influenza vaccine | |
| Riaz et al. | Comparative efficacy of different adjuvant containing inactivated vaccines against low-pathogenicity Avian Influenza H9N2 virus |